Rituximab and Ocrelizumab in Serum With Multiple Sclerosis (ROS-MS)
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: f
View:
• Included in OVERLORD-MS (NCT04578639)
• Willing to attend laboratory for blood sample collection at scheduled time points
Locations
Other Locations
Norway
Haukeland University Hospital, Deparment of medical biochemistry and pharmacology
RECRUITING
Bergen
Contact Information
Primary
Trond T. Serkland, M.D.
trond.tretteberg.serkland@helse-bergen.no
004755975563
Backup
Silje Skrede, M.D., PhD
silje.skrede@helse-bergen.no
Time Frame
Start Date: 2021-03-15
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 60
Related Therapeutic Areas
Sponsors
Collaborators: University of Bergen
Leads: Haukeland University Hospital